GABA System in Anxiety Disorders: A Review of Current and Novel GABAergic Drugs

Yuke Cai, Enze XuJournal of Education Humanities and Social Sciences 2023 · DOI

TL;DR

This review evaluates the shift in pharmacological anxiety treatment from traditional benzodiazepines to novel GABAergic compounds. The authors highlight BNC-210 and SAGE-217 as the most promising candidates, offering significant anti-anxiety effects with fewer sedative and addictive side effects than current gold-standard treatments.

What Problem Does This Paper Address?

Anxiety disorders, including Generalized Anxiety Disorder (GAD) and Social Anxiety Disorder (SAD), represent a massive global health burden. While Benzodiazepines have been the mainstay of treatment for decades due to their rapid action on the GABA-A receptor, they come with a heavy "side-effect tax": drowsiness, memory impairment, confusion, and a high risk of dependence.

The challenge lies in finding medications that harness the inhibitory power of the GABA system—the brain's primary "braking" mechanism—without the blunt-force trauma of total sedation. This paper reviews the efficacy and safety profiles of current off-label drugs (like antiepileptics) versus a new wave of subtype-selective and neurosteroid-based medications.

Methods

As a literature review, the authors synthesized findings from 29 authoritative sources, including clinical trials (Phase I and II), meta-analyses, and animal models. They categorized the drugs into two groups:

  1. Current GABAergic Drugs: Primarily repurposed antiepileptics like Levetiracetam, Gabapentin, Pregabalin, and Tiagabine.
  2. Novel GABAergic Drugs: Newer compounds specifically engineered for higher receptor specificity or alternative pathways, including AZD7325, PF-06372865, BNC-210, and SAGE-217.

The evaluation focused on the trade-off between "anxiolytic" (anxiety-reducing) efficacy and "adverse events" (side effects).

Datasets

The paper does not introduce a new dataset but relies on established clinical benchmarks and diagnostic criteria, such as:

  • DSM-5: For the categorization of anxiety disorders.
  • Hamilton Anxiety Rating Scale (HAM-A): Used across multiple cited studies to quantify symptom reduction.
  • Zung Self-Rating Scale: For patient-reported outcomes.
  • Clinical Trial Data: Results from various Phase I and II trials conducted by pharmaceutical entities.

Key Insights and Ideas

  • The Subtype Selectivity "Holy Grail": Traditional drugs are often non-selective. The paper discusses the push toward targeting specific GABA-A receptor subunits (like $\alpha2$ and $\alpha3$) to achieve anti-anxiety effects while avoiding the $\alpha1$ subunit, which is linked to sedation and addiction.
  • Repurposing Antiepileptics: While drugs like Levetiracetam show promise in animal models, they often fail in human trials for severe social anxiety, suggesting their "multitargeting" nature might be too diluted for psychiatric use.
  • BNC-210’s Unique Path: Unlike direct GABA agonists, BNC-210 is a nicotinic receptor alpha7 negative-allosteric modulator. It appears to regulate amygdala hyperactivity indirectly, potentially offering a "cleaner" side-effect profile.
  • SAGE-217 (Zuranolone): This neuroactive steroid acts as a positive allosteric modulator of GABA-A receptors. It has shown rapid, significant results in treating postpartum depression and anxiety, marking a shift toward fast-acting, hormone-based neuro-modulation.

Key Results

  • BNC-210 & SAGE-217: Identified as the top performers. BNC-210 was shown to reduce the brain's reaction to fearful stimuli in GAD patients more effectively than placebos or lorazepam, with only mild side effects.
  • Pregabalin vs. Benzodiazepines: Meta-analyses showed that Pregabalin has lower dropout rates and no withdrawal syndrome compared to benzodiazepines, though it still carries some risk of dependence in vulnerable populations.
  • The Failures: AZD7325 and PF-06372865 faced setbacks because their clinical performance failed to significantly separate from placebos in Phase II trials, leading to the termination of some development paths.
  • Tiagabine: While effective for some, it was found to be less effective than common antidepressants (SSRIs/SNRIs) and had poorer tolerability.

Limitations and Future Work

The authors acknowledge several hurdles for the field:

  • Evidence Gap: Novel drugs like BNC-210 and SAGE-217 lack the decades of longitudinal data that current drugs possess. More large-scale, late-stage (Phase III) trials are required.
  • Sample Sizes: Many studies on repurposed drugs like Levetiracetam suffer from small sample sizes, which limits the generalizability of the findings.
  • Precision Medicine: The authors suggest that the future of anxiety treatment may lie in "gene testing" to recommend specific medications based on an individual's unique neurochemistry, rather than the current trial-and-error approach.
  • Broadening Scope: Future research should investigate if these novel GABAergic drugs are effective for comorbid conditions, such as bipolar disorder or physical manifestations of stress.

Summary updated

Abstract

This is an article for defying diverse of drugs in GABA system showing effect in treating anxiety or not. In the passage, the authors discuss the effect and side effect of levetiracetam, gabapentin and pregabalin, tiagabine, and several novel medications which are AZD7325, PF-06372865, BNC-210, SAGE-217. Some of these drugs were certified and has been put into use for decades, while others may be lack of solid test or further experiment for treating anxiety disorders. The main aim of review is evaluating the recent evidence to find out the included GABAergic drugs’ potential that is most likely to be beneficial for future therapy of treating anxiety disorders, listing the effect and side effect according to the research, and making comparison to other types of anti-anxieties. In the result, BNC-210 and SAGE-217, as the novel GABAergic drug, are more effective than others, also with less and mild side effects. All the evidence are collected from the papers that written by authorities.
BibTeX
@article{cai2023gaba,
  author = {Yuke Cai and Enze Xu},
  title = {{GABA System in Anxiety Disorders: A Review of Current and Novel GABAergic Drugs}},
  journal = {Journal of Education Humanities and Social Sciences},
  year = {2023},
  doi = {10.54097/ehss.v22i.12411},
}
Figure